Summary
We have previously shown that long-term administration of aminoguanidine, an inhibitor of advanced glycosylation product formation, reduces the extent of experimental diabetic retinopathy in the rat by 85%. In order to determine whether the residual retinopathy that developed despite aminoguanidine was attributable to advanced glycation endproduct formation, a time-course study was performed in three different groups of male Wistar rats: non-diabetic controls (NC), streptozotocin-diabetic controls (DC) and streptozotocin-diabetic rats treated with aminoguanidine HCL, 50 mg/100 ml drinking water (D-AG). Eyes were obtained at 24, 32, 44 and 56 weeks of diabetes/treatment duration and morphologic evaluation was done on retinal digest preparations. At 56 weeks, retinal basement membrane thickness was additionally measured. After 24 weeks of diabetes, the number of acellular capillaries was significantly elevated in DC (44.6±5.7/mm2 of retinal area, NC 19.6±4.9; p<0.001) and increased continuously over time (DC 56 weeks 87.4±15.1; p<0.001 vs DC 24 weeks). In contrast, acellular capillaries in D-AG increased over the first 24 weeks and then remained constant for the rest of the study (D-AG 24 weeks 35.7±5.18; p<0.01 vs NC 24 weeks and NS vs DC 24 weeks; D-AG 56 weeks 42.0±6.20; p NS vs D-AG 24 weeks). Diabetes-associated pericyte loss (DC 24 weeks 2310±170/mm2 of capillary area; NC 24 weeks 3120±190; p<0.001; DC 56 weeks 1570±230; NC 56 weeks 2960±50; p<0.001) was significantly prevented by aminoguanidine after diabetic-like changes over the initial 24 weeks (D-AG 24 weeks 2450±75; p NS vs DC 24 weeks; D-AG 56 weeks 2350±90; p<0.001 vs DC 56 weeks). At 56 weeks, aminoguanidine treatment was associated with a 67.4% reduction in retinal basement membrane thickening. This time-course study demonstrates that aminoguanidine prevents the progression of experimental diabetic retinopathy, and suggests that non AG-inhibitable mechanisms are involved in the initial phase of diabetic retinopathy.
Article PDF
Similar content being viewed by others
Abbreviations
- NC:
-
Non-diabetic controls
- DC:
-
diabetic controls
- D-AG:
-
diabetic rats treated with aminoguanidine
- AG:
-
aminoguanidine
- AGE:
-
advanced glycation end products
- STZ:
-
streptozotocin
- PAS:
-
periodic acid Schiff
References
Klein R, Klein BEK, Moss S et al. (1984) The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 102:520–526
Weber B, Burger W, Hartmann R et al.(1986) Risk factors for the development of retinopathy in children and adolescents with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 29:23–29
Janka HU, Warram JH, Rand LI et al. (1989) Risk factors for the progression of background retinopathy in long-standing IDDM. Diabetes 38:460–464
Chase HP, Jackson WE, Hoops SL et al. (1989) Glucose control and the renal and retinal complications of insulin-dependent diabetes. JAMA 261:1155–1160
Engerman RL, Kern TS (1987) Progression of diabetic retinopathy during good glycemic control. Diabetes 36:808–812
Constam GR (1977) Sind die diabetische Angio- und Neuropathie vermeidbar? Med Klinik 72:695–702
Hanssen KF, Bangstad H-J, Brichmann-Hansen O, Dahl-Jorgensen K (1992) Blood glucose control and diabetic microvascular complications: long-term effects of near-normoglycemia. Diabet Med 9:697–705
Brownlee M, Vlassara H, Cerami A (1988) Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318:1315–1321
Hammes HP, Martin S, Federlin K et al. (1991) Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Nat Acad Sci USA 88:11555–11558
Hammes HP, Brownlee M, Edelstein D et al. (1994) Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia 37:32–35
Kuwabara T, Cogan DG (1960) Studies of retinal vascular patterns. I. Normal architecture. Arch Ophthalmol 64:904–911
Syed Ali S (1984) Angio architecture of the pancreas of the cat. Light-, scanning- and transmission electron microscopy. Cell Tissue Res 235:675–682
Carlson EC, Bjork NJ (1990) SEM and TEM analysis of isolated human retinal microvessel basement membranes in diabetic retinopathy. Anat Rec 226:295–306
Sachs L (1992) Angewandte Statistik. 7th edn. Springer, Berlin Heidelberg New York London Paris Tokyo Hong Kong Barcelona Budapest
Brownlee M, Vlassara H, Cerami A (1988) Advanced glycosylation endproducts and the biochemical basis of complications. Beth Israel Seminar in Medicine. N Engl J Med 318:1315–1321
Higgins PJ, Bunn HF (1981) Kinetic analysis of the non-enzymatic glycosylation of haemoglobin. J Biol Chem 256:5204–5208
Mortensen HB, Christophersen C (1983) Glycosylation of human haemoglobin A in red blood cells studied in vitro. Kinetics of the formation and dissociation of haemoglobin A1c. Clin Chim Acta 134:317–326
Makita Z, Vlassara H, Rayfield E et al. (1992) Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science 258:651–653
Brownlee M, Vlassara H, Cerami A (1984) Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Int Med 101:527–537
Brownlee M (1990) Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic complications. In: Rifkin H, Porte D Jr (eds) Diabetes mellitus. Theory and Practice. Alan R Liss, New York, pp 279–291
Kato H, Hayase F, Shin DB et al. (1989) 3-Deoxyglucasone, an intermediate product of the Maillard reaction. In: Baynes JW, Monnier VM (eds) Proceedings of the NIH Conference on the Maillard Reaction in Aging, Diabetes and Nutrition. Alan R Liss, New York, pp 69–84
Fu MX, Wells-Knecht KJ, Blackledge JA et al. (1994) Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the maillard reaction. Diabetes 43:676–683
Mullarkey CJ, Edelstein D, Brownlee M (1990) Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun 173:932–939
Kent MJC, Light ND, Bailey AJ (1985) Evidence for glucose-mediated covalent cross-linking of collagen after glycosylation in vitro. Biochem J 225:745–752
Brownlee M, Vlassara H, Cerami A (1985) Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein. Diabetes 34:983–941
Vlassara H, Brownlee M, Cerami A (1985) High-affinity receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. Proc Nat Acad Sci USA 82:5588–5592
Vlassara H, Brownlee M, Monogue K et al. (1988) Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodelling. Science 240:1546–1548
Rohrbach DH, Martin GR (1982) Structure of basement membrane in normal and diabetic tissue. Ann NY Acad Sci 401:203–211
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hammes, H.P., Syed Ali, S., Uhlmann, M. et al. Aminoguanidine does not inhibit the initial phase of experimental diabetic retinopathy in rats. Diabetologia 38, 269–273 (1995). https://doi.org/10.1007/BF00400629
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00400629